| Roger B Rehr, MD | |
|
301 S 7th Ave, Suite 2020, West Reading, PA 19611-1410 | |
| (610) 375-6565 | |
| (610) 375-2065 |
| Full Name | Roger B Rehr |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 301 S 7th Ave, West Reading, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184603615 | NPI | - | NPPES |
| 1211350 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD-023083-E (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Roger B Rehr, MD 301 S 7th Ave, Suite 2020, West Reading, PA 19611-1410 Ph: (610) 375-6565 | Roger B Rehr, MD 301 S 7th Ave, Suite 2020, West Reading, PA 19611-1410 Ph: (610) 375-6565 |
News Archive
Mutations in the insulin gene can cause permanent neonatal diabetes, an unusual form of diabetes that affects very young children and results in lifelong dependence on insulin injections, report researchers from the University of Chicago and Peninsula University (Exeter, UK) in Sept. 18, 2007, issue of the Proceedings of the National Academy of Sciences, published early online.
Using sophisticated new software that integrates a variety of imaging methods, Wake Forest University Baptist Medical Center researchers will probe the mystery of what causes dyslexia with a four-year, $2.3 million grant from the National Institutes of Health.
Researchers at Case Western Reserve University will use a $2 million grant from the National Institutes of Health to develop and test a small, portable blood-adhesion monitor for sickle cell disease patients.
"In a move that could lead to a new milestone for treatment in the evolution of the worldwide AIDS epidemic," a Food and Drug Administration (FDA) panel on Thursday recommended Gilead Sciences' Truvada as a treatment for preventing HIV infection among healthy people at risk of contracting the virus, Reuters reports, noting, "It already has FDA approval to treat people infected with the human immunodeficiency virus".
Seattle Genetics, Inc. today announced that its phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) did not meet its primary endpoint of extending overall survival. Lintuzumab is a naked monoclonal antibody that targets the CD33 antigen. As a result of the outcome of this trial, the company will discontinue its development program for lintuzumab.
› Verified 9 days ago
Ankush Lahoti, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave, Suite 2020, West Reading, PA 19611 Phone: 610-375-6565 Fax: 610-375-2065 | |
Tayyab Ali Waheed, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8640 Fax: 484-628-9003 | |
Nyein Yu, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-5455 | |
Richard Loynd, D.O. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6th Avenue And Spruce Street, West Reading, PA 19611 Phone: 484-628-8640 Fax: 484-628-9003 | |
Krysta Brown, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave Ste 340, West Reading, PA 19611 Phone: 484-628-8640 Fax: 484-628-9003 | |
Niranjan Tachamo, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-5455 | |
Earl J Hope, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 301 S 7th Ave, Suite 2020, West Reading, PA 19611 Phone: 610-375-6565 Fax: 610-375-2065 |